Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The CCNE2 mRNA 3' untranslated region (3' UTR) is a critical regulatory segment of the messenger RNA encoding Cyclin E2, a protein essential for the G1/S phase transition in the cell cycle. This region contains multiple binding sites for microRNAs (miRNAs) and RNA-binding proteins that dictate the stability and translation efficiency of the CCNE2 transcript (Caldon et al., 2013, PubMed). In many cancers, including breast and lung cancer, the loss of inhibitory miRNA binding or the shortening of the 3' UTR leads to the overexpression of Cyclin E2, which drives uncontrolled cellular proliferation and contributes to endocrine therapy resistance (Balko et al., 2014, Nature Medicine). As a therapeutic target, the CCNE2 mRNA 3' UTR is primarily addressed using miRNA mimics or antisense oligonucleotides designed to restore translational repression or induce transcript degradation. By modulating this regulatory node, researchers aim to arrest the cell cycle in malignant cells and sensitize tumors to existing chemotherapeutic or endocrine agents.
MicroRNA-mediated gene silencing, mRNA degradation, Translational inhibition
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclin E2 mRNA 3' untranslated region (CCNE2 mRNA 3' UTR).